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Supplementary Figure 1. Representative image of electron microscopy of renal biopsy from 












Supplementary Figure 2. Clinical finding of ichthyosis for patient 7, hyperpigmentation as a 










Supplementary Figure 3. Cranial MRI of patient 5 showing the progressive nature of her disease, 
aged 8m and 4.3yr. At 4.3 yr (right panel), hyperintensity is seen in the globus pallidus (green 
arrow), medial thalamic nuclei (blue arrow) and pons (red arrow). These features were not seen on 








Supplementary Figure 4. Plasma sphingolipid intermediate levels, assayed by mass spectrometry, 







Supplementary Figure 5. SGPL1 expression in the tubules and glomeruli in normal human adult 
kidney; within the glomerulus staining is apparent predominantly in podocytes (arrowed); Source: 
Human protein atlas (http://www.proteinatlas.org/) where sections from a normal adult human 
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10 72619205 C Exonic SGPL1 p.I188I T T synonymous 
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Supplementary Table 2. Further details of kidney biopsy results for patients with SRNS 
Patient Biopsy report 
1A Light microscopy: Focal segmental glomerulosclerosis 
 
Immunofluorescence: Granular membrane and mesangial positivity of IgM, weak 
positivity of C3 and C1q in the same distribution; IgG and IgA negative 
5 Light microscopy: Focal segmental glomerulosclerosis, tubular regenerative changes 
 
Immunofluorescence: Glomerular/ focal/ segmental positivity of IgM, C3 positive, kappa/ 
λ weakly positive; IgG negative, IgA negative, C19 negative 
 
Electron microscopy: Vacuolisation of tubular podocytes, podocyte foot process 
effacement and conglomeration, increased numbers of abnormally shaped mitochondria 
in tubules (rectangular, comma shaped swollen mitochondria) 
6 Light microscopy: 20 glomeruli with more than 10 showing global sclerosis.  Increase in 
mesangial matrix and mesangial hypercellularity. Adhesion the Bowman´s capsule.  2 
glomeruli with cellular crescents.  Interstitial: Tubular dilatations and tubular atrophy 
 
Immunofluorescence: IgM positive, IgA negative, IgG negative; C3  positive, C1q negative 
 
7 Light microscopy:  Nine glomeruli, one collapse. Increase in mesangial matrix and 
mesangial hypercellularity. Adhesion the Bowman’s capsule.  Podocyte hyperplasia and 










Supplementary Table 3. Immunophenotyping of Patient 5. Sampling at 5.9 yr, techniques as 
previously described (1); Peripheral blood lymphocyte numbers: 1000 cells/μl; 19.4% of total 
leucocyte count (NR 21-40)). TCR αβ; T-cell receptor (TCR) α- and β-chain, TCR Ƴδ; T-cell receptor 
(TCR) Ƴ- and δ-chain. 
 
Subset % Cells  Cells/μl Normal range 
(NR) 
Comment 
CD3+  64.9 640 (>700) Low 
CD3+ CD4+ 30.3 300 (>300) Normal 
CD3+ CD8+ 27.1 270 (>300) Low 
CD3+CD4−CD8−  2.09   Normal 
T cell repertoire 
(TCR αβ) 
92   Normal 
T cell repertoire 
(TCR ƴΔ) 
7.5   Normal 
CD3+/HLADR+ 8.8  (3-14%) Normal 
Recent thymic 
emigrant (RTE) 
61.4  (41-81%) Normal 
Naïve CD4+ 29.8 (53-86)  Low 
Memory CD4+ 43.4 (9-26)  High 
Naïve CD8+ 60.8 (>69)  Low 
Memory CD8+ 40 (4-16)  High 
CD19+  160 (>200) Low 
CD16+/CD56+  140 (>90) Normal 
Class-switched B cell 12.2  (>10.9%) Normal 
Unclass-switched B 
cell 
20.5  (5.2-20.4%) Normal 
9 
 
Transitional B cell 1.03  (>4.6%) Low 





Supplementary Table 4. T lymphocyte proliferation assay of Patient 5 




CD mixC (%) 
Patient 5 5 41 66.7 
Age and sex matched 
control 
6 23.4 40.4 
 
The ability of T lymphocytes to proliferate in response to Asaline, a Bmitogen (Phytohaemagluttinin) 
or Canti–T cell receptor (anti-CD3/CD28 antibody; CD mix) was determined in vitro. Relative T cell 
expansion is compared to an age and sex matched control. Assays performed at 5.9 yr, techniques as 




Supplementary Table 5. Primer Sequences 
Name Sequence (5’ to 3’) 
SGPL1 EX2 for AGGAGGGAGAGAACCATAACT 
SGPL1 EX2 rev AGCAAGCATCAGAGGTGA 
SGPL1 EX3 for GAATGACCTTGCCCTTGA 
SGPL1 EX3 rev ACTCCAGCCTAGCAACAGA 
SGPL1 EX4 for ACTCTTTGCAATTGGAAGG 
SGPL1 EX4 rev CCTCCACTTTGAGAATATTAGGTT 
SGPL1 EX5 for AGCAGTTGCTTGACTGTCA 
SGPL1 EX5 rev GAAATTCAACCTGTGAAACAG 
SGPL1 EX6 for ATCCAGAGGAGTTTCTTCCT 
SGPL1 EX6 rev AAGGAGGTCATGTAAACTGG 
SGPL1 EX7 for ACTGTTGTTTAGTGCATGATTCT 
SGPL1 EX7 rev ACTGCAGTTAATTAGGATCTTTG 
SGPL1 EX8 for GAAATCGTGAGGATAGCTTG 
SGPL1 EX8 rev CACAATCTTCATCCCAAAG 
SGPL1 EX9 for GAACTTACTCCCGGTAATTTAGA 
SGPL1 EX9 rev GTCAGACCCATCTGACTGG 
SGPL1 EX10 for CTGGAACTCTAAGCTAGCAGC 
SGPL1 EX10 rev GAGCTACTTATCACTACTGTGGTCA 
SGPL1 EX11 for CATCTTTCCACCCATGTCT 
SGPL1 EX11 rev GTGACGGCAAAGAGAGAGT 
SGPL1 EX12 for TGCATGATGAGAGTTCTGG 
SGPL1 EX12 rev GAGACAACAGGTGGGCTA 
SGPL1 EX13 for GTGACCAGGGGATTGTATG 
12 
 
SGPL1 EX13 rev TTGCTACTAACGTGCTAGCCT 
SGPL1 EX14 for CTTGTCAGAAATATTGTGAAAGG 
SGPL1 EX14 rev CAGACTCCGGGTCATATG 
SGPL1 EX15 for AGTGCACATGCGAAGCTA 
SGPL1 EX15 rev GAGGCTCAAGCTGTCTCAT 
SGPL1 cDNA for 
 
TGGAGATTTTGCATGGAG 
SGPL1 cDNA rev 
 
CACCTCCATCATCTTCGT 
SGPL1 cDNA for 2 
 
GATATCTTCCCAGGACTACG 
SGPL1 cDNA rev 2 
 
CATCATCTTCGTCAATGG 
GAPDH cDNA for 
 
GAAGGTGAAGGTCGGAGTC 




















Supplementary Table 6. Primer sequences for site directed mutagenesis 
Name Sequence (5’ to 3’) 
SGPL1 ‘p.R222Q’ for GCCTGCAAAGCATATCAGGATCTGGCCTTTGAG 
SGPL1 ‘p.R222Q’ rev CTCAAAGGCCAGATCCTGATATGCTTTGCAGGC 
SGPL1 ‘p.F545del’ for CAGAATTGTCCTCAGTCTTGGACAGCTTGTACAG 
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